
Quarterly report 2023-Q3
added 11-14-2023
Adamis Pharmaceuticals Corporation Financial Statements 2011-2026 | ADMP
Annual Financial Statements Adamis Pharmaceuticals Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
18 M | 86.5 M | 61.3 M | 35.7 M | 121 M | 103 M | 54.3 M | 63.1 M | 39.8 M | 49.8 M | 58.2 M | 14.7 M |
Shares |
150 M | 144 M | 53.3 M | 53.3 M | 39.1 M | 28.3 M | 17.5 M | 13.3 M | 7.35 M | 5.86 M | 5.26 M | 3.75 M |
Historical Prices |
0.12 | 0.6 | 1.15 | 0.66 | 3.07 | 3.65 | 3.1 | 4.75 | 6.82 | 6.66 | 11.6 | 2.89 |
Net Income |
-26.5 M | -45.8 M | -49.4 M | -29.3 M | -39 M | -25.5 M | -19.4 M | -13.6 M | -8.16 M | -7.19 M | -4.92 M | -6.98 M |
Revenue |
4.76 M | 2.21 M | 16.5 M | 22.1 M | 15.1 M | 13.1 M | 6.47 M | - | - | - | - | - |
Cost of Revenue |
6.19 M | 6.87 M | 6.33 M | 15.5 M | 9.8 M | 7.42 M | - | - | - | - | - | - |
Gross Profit |
-1.43 M | -4.66 M | 1.63 M | 6.64 M | 5.29 M | 5.65 M | 1.62 M | - | - | - | - | - |
Operating Income |
-25.1 M | -32.1 M | -36.3 M | -29.4 M | -39.5 M | -24.8 M | -25.2 M | -13.9 M | -9.72 M | -3.22 M | -4.82 M | -6.24 M |
Interest Expense |
- | - | 4.92 K | 123 K | 158 K | 231 K | 214 K | - | 372 K | 2.33 M | 35.4 K | 744 K |
EBITDA |
-23.6 M | -30.6 M | -33.6 M | -26.1 M | -36.4 M | -21.6 M | -22.7 M | -12.9 M | -4.1 M | -3.22 M | -4.82 M | -6.23 M |
Operating Expenses |
- | - | 38.9 M | 35.7 M | 44.7 M | 30.3 M | 26.8 M | 13.9 M | 4.4 M | 3.22 M | 4.82 M | 6 M |
General and Administrative Expenses |
13.2 M | 16.1 M | - | 25.3 M | 25.9 M | 22.8 M | 17.1 M | 9.01 M | 3.39 M | 2.01 M | 2.9 M | 3.37 M |
All numbers in USD currency
Quarterly Income Statement Adamis Pharmaceuticals Corporation
| 2023-Q3 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
7.07 M | 153 M | 2.14 M | 2.14 M | 150 M | 150 M | 150 M | 149 M | 149 M | 129 M | 93.8 M | 76 M | 73.8 M | 66.5 M | 61.8 M | 56.3 M | 47.5 M | 47.3 M | 47.3 M | 42.1 M | 33.4 M | 33.4 M | 33.4 M | 31.5 M | 26.2 M | 22.1 M | 22 M | 19.6 M | 15.4 M | 13.4 M | 13.4 M | 13.4 M | 13.4 M | 12.8 M | 10.7 M | 10.5 M | 10.5 M | 10.4 M | 6.74 M | 6.17 M | 6.16 M | 6.14 M | 5.81 M | 5.77 M | 97.7 M | 95.9 M | 91.9 M | 87.8 M | 85.9 M | 81.6 M |
Net Income |
-1.39 M | -8.94 M | - | -4.4 M | -8.4 M | -10.4 M | - | -12.4 M | -9.31 M | -15.4 M | - | -11.4 M | -12.9 M | -7.25 M | - | -7 M | -7.74 M | -8.89 M | - | -8.88 M | -9.7 M | -7.62 M | - | -6.77 M | -4.97 M | -5.77 M | - | -6.64 M | -5.71 M | -6.41 M | - | -3.15 M | -3.64 M | -3.14 M | - | -2.12 M | -2.88 M | -1.55 M | -5.53 M | -32 K | -1.07 M | - | -1.97 M | -5.56 M | -3.58 M | - | -991 K | -3.71 M | -2.72 M | - |
Revenue |
9.06 K | 1.45 M | - | 1.51 M | 39.8 K | 1.15 M | - | 760 K | 1.28 M | 1.39 M | - | 868 K | 3.93 M | 4.66 M | - | 5.9 M | 5.76 M | 4.91 M | - | 3.83 M | 3.92 M | 3.18 M | - | 3.39 M | 3.81 M | 3.04 M | - | 2.08 M | 1.93 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
338 K | 1.79 M | - | 1.65 M | 689 K | 1.46 M | - | 1.57 M | 1.8 M | 1.85 M | - | 1.41 M | 4.68 M | 3.69 M | - | 3.99 M | 3.67 M | 3.63 M | - | 2.3 M | 2.39 M | 2.06 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
-329 K | -335 K | - | -142 K | -649 K | -309 K | - | -806 K | -521 K | -452 K | - | -546 K | -757 K | 976 K | - | 1.91 M | 2.1 M | 1.28 M | - | 1.53 M | 1.53 M | 1.12 M | - | 1.3 M | 1.92 M | 1.37 M | - | 255 K | 582 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
-3.27 M | -6.43 M | - | -4.63 M | -8.18 M | -7.91 M | - | -10.2 M | -7.65 M | -6.22 M | - | -5.5 M | -11.2 M | -10.3 M | - | -7.01 M | -7.75 M | -8.94 M | - | -8.91 M | -9.67 M | -7.61 M | - | -5.8 M | -4.92 M | -5.71 M | - | -6.58 M | -7.43 M | -6.02 M | - | -3.31 M | -3.53 M | -4.15 M | - | -1.94 M | -2.75 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
Interest Expense |
29.5 K | -113 K | - | 278 K | - | -440 K | - | 1.86 K | 2.9 K | 1.88 K | - | 1.72 K | 32.9 K | 38.3 K | - | 21.9 K | 23 K | 24 K | - | 30.7 K | 51.4 K | 50.7 K | - | 52.6 K | 59.4 K | 67.5 K | - | 70.2 K | 72.4 K | - | - | - | - | - | - | 371 K | 226 K | 145 K | 5.3 M | 2.78 M | 3.18 M | - | 845 K | 1.72 M | 874 K | - | 2.61 K | 32.7 K | 30.1 K | - |
EBITDA |
-3.2 M | -6.32 M | - | -4.23 M | -7.81 M | -7.57 M | - | -9.85 M | -7.28 M | -5.89 M | - | -4.61 M | -10.4 M | -9.34 M | - | -6.19 M | -7.04 M | -8.1 M | - | -6.59 M | -8.13 M | -6.84 M | - | -3.48 M | -3.36 M | -4.93 M | - | -4.82 M | -7.28 M | -5.77 M | - | -2.56 M | -3.04 M | -3.9 M | - | -1.05 M | -2.45 M | -1.71 M | -984 K | -957 K | -1.7 M | - | -748 K | -2.32 M | -1.58 M | - | -989 K | -3.68 M | -2.69 M | - |
General and Administrative Expenses |
2.52 M | 4.78 M | - | 2.51 M | 4.21 M | 3.38 M | - | 4.79 M | 4.93 M | 3.52 M | - | 3.31 M | 5.65 M | 6.05 M | - | 5.3 M | 7 M | 8.02 M | - | 6.53 M | 6.36 M | 6.47 M | - | 5.75 M | 5.66 M | 5.57 M | - | 5.34 M | 4.58 M | 2.62 M | - | 2.13 M | 2.26 M | 2.79 M | - | 1.34 M | 1.01 M | 1.34 M | 776 K | 762 K | 1.28 M | - | 542 K | 1.59 M | 1.05 M | - | 807 K | 2.3 M | 1.49 M | - |
All numbers in USD currency
Main types of financial statements Adamis Pharmaceuticals Corporation ADMPFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting Adamis Pharmaceuticals Corporation plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Drug manufacturers industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
- | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
- | 10.11 % | $ 58.2 M | ||
|
Aerie Pharmaceuticals
AERI
|
- | - | $ 754 M | ||
|
Alimera Sciences
ALIM
|
- | - | $ 142 M | ||
|
Canopy Growth Corporation
CGC
|
$ 1.14 | -4.62 % | $ 123 M | ||
|
Cronos Group
CRON
|
$ 2.56 | 1.24 % | $ 1.35 B | ||
|
Cumberland Pharmaceuticals
CPIX
|
$ 4.74 | 1.94 % | $ 66.6 M | ||
|
Catalent
CTLT
|
- | - | $ 11.5 B | ||
|
Eagle Pharmaceuticals
EGRX
|
- | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
- | - | $ 28.9 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
- | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
- | 2.45 % | $ 38.1 M | ||
|
Evoke Pharma
EVOK
|
- | - | $ 36.6 M | ||
|
DURECT Corporation
DRRX
|
- | - | $ 50.1 M | ||
|
Emergent BioSolutions
EBS
|
$ 11.08 | 0.82 % | $ 567 M | ||
|
Athenex
ATNX
|
- | -23.39 % | $ 1.76 M | ||
|
Evolus
EOLS
|
$ 5.05 | -2.88 % | $ 313 M | ||
|
Harrow Health
HROW
|
$ 47.49 | -0.86 % | $ 1.55 B | ||
|
China Pharma Holdings
CPHI
|
$ 1.25 | - | $ 21.8 M | ||
|
Jupiter Wellness
JUPW
|
- | - | $ 33.6 M | ||
|
OrganiGram Holdings
OGI
|
$ 1.62 | 0.62 % | $ 402 M | ||
|
Bausch Health Companies
BHC
|
$ 6.75 | -3.3 % | $ 2.46 B | ||
|
Neoleukin Therapeutics
NLTX
|
- | - | $ 193 M | ||
|
Lannett Company
LCI
|
- | 1.15 % | $ 7.11 M | ||
|
Sundial Growers
SNDL
|
$ 1.58 | -2.17 % | $ 3.37 M | ||
|
Organogenesis Holdings
ORGO
|
$ 3.64 | -3.96 % | $ 479 M | ||
|
Pacira BioSciences
PCRX
|
$ 19.43 | 1.38 % | $ 899 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
$ 21.51 | 0.14 % | $ 2.05 B | ||
|
PetIQ
PETQ
|
- | 1.64 % | $ 400 M | ||
|
Perrigo Company plc
PRGO
|
$ 15.06 | 0.2 % | $ 2.07 B | ||
|
Aurora Cannabis
ACB
|
$ 4.14 | -2.13 % | $ 86.3 M | ||
|
ProPhase Labs
PRPH
|
- | - | $ 5.07 M | ||
|
Recro Pharma
REPH
|
- | -4.76 % | $ 65.3 M | ||
|
Rockwell Medical
RMTI
|
$ 1.22 | 27.44 % | $ 28.5 M | ||
|
Radius Health
RDUS
|
- | - | $ 1.42 B | ||
|
Sonoma Pharmaceuticals
SNOA
|
$ 3.33 | 1.06 % | $ 4.13 M | ||
|
Relmada Therapeutics
RLMD
|
$ 3.93 | 5.01 % | $ 118 M | ||
|
OptiNose
OPTN
|
- | - | $ 1.08 B | ||
|
Assertio Holdings
ASRT
|
$ 12.04 | 4.88 % | $ 855 M | ||
|
Tilray
TLRY
|
$ 8.74 | -7.62 % | $ 5.4 B | ||
|
PLx Pharma
PLXP
|
- | -27.8 % | $ 2.56 M | ||
|
Solid Biosciences
SLDB
|
$ 5.59 | 2.19 % | $ 228 M | ||
|
SCYNEXIS
SCYX
|
$ 0.65 | -0.68 % | $ 31.1 M | ||
|
Tricida
TCDA
|
- | - | $ 3.25 M | ||
|
Veru
VERU
|
$ 2.53 | -5.95 % | $ 341 M | ||
|
TherapeuticsMD
TXMD
|
$ 2.55 | 14.39 % | $ 26.6 M | ||
|
Viatris
VTRS
|
$ 12.66 | -1.59 % | $ 15.3 B | ||
|
Zomedica Corp.
ZOM
|
- | -0.21 % | $ 98 M | ||
|
cbdMD
YCBD
|
$ 0.83 | -9.94 % | $ 3.58 M |